NCT06349837 2025-12-17
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
Phase 1 Recruiting
Sichuan University
Centre Hospitalier Universitaire Dijon
InnoBM Pharmaceuticals Co., Ltd.